The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response

Amanda F. Baker, Terry Landowski, Robert Dorr, Wendy R. Tate, Jaime M. C. Gard, Breonna E. Tavenner, Tomislov Dragovich, Amy Coon, and Garth Powis

Abstract

Purpose: The aim of this study was to identify biomarkers that may be predictive for the clinical activity of the redox-active antitumor agent imexon.

Experimental Design: cDNA microarray and quantitative real-time PCR were used to identify global changes in gene expression in peripheral blood mononuclear cells (PBMC) collected from patients treated with imexon during a phase I trial. Electrophoretic mobility shift assays and Western blot analysis were done using the RPMI8226 myeloma cell line grown in vitro and PBMCs treated ex vivo to investigate the molecular mechanism responsible for these gene changes.

Results: Both cDNA microarray and quantitative real-time PCR showed the up-regulation of many antioxidant genes, including thioredoxin reductase-1, glutaredoxin-2, and peroxiredoxin-3 in PBMCs collected from patients treated with imexon. Studies in PBMCs treated ex vivo and RPMI8226 myeloma cells showed that imexon increased binding to the activator protein-1 consensus sequence measured by electrophoretic mobility shift assay. Supershift analysis showed that the majority of the activator protein-1 DNA binding activity was c-Jun, with minor contribution of Jun-D. Nuclear translocation of the nuclear factor (erythroid-derived 1)-like 2 transcription factor and its binding to the antioxidant response element was also increased after imexon treatment, which correlated with an increase in the message levels for nuclear factor (erythroid-derived 1)-like 2/antioxidant response element–regulated antioxidant genes.

Conclusions: Together, these results show that a predominant biological effect of imexon is a change in redox state that can be detected in surrogate normal tissues as increased redox-sensitive transcription factor binding and increased antioxidant gene expression.

Imexon is an aziridine-containing iminopyrrolidone that shows promising in vitro and in vivo antitumor activity in myeloma, lymphoma, and pancreatic cancer cell line models (1–3). Imexon was tested for anticancer activity in a limited number of clinical trials in the early 1970s (4). Although it was found to be relatively nontoxic at low, fixed doses in few patients, it was not developed further as an anticancer agent. Recently, imexon has again entered phase 1 clinical trials in patients with advanced solid malignancies.

Preclinical studies have shown that imexon reacts with sulphydryl groups resulting in cellular thiol depletion, an increase in oxidative stress superoxide anion radical formation, mitochondrial alterations, and apoptosis (5–7). Consistent with this mode of action, an imexon-resistant RPMI8226 myeloma cell line was shown to overexpress thioredoxin-2, a mitochondrial member of the thioredoxin family of redox proteins, which protect against apoptosis (8). In addition, this cell line displayed cross-resistance with other chemotherapeutic agents known to induce oxidative stress, including doxorubicin and arsenic trioxide.

Protection against oxidative stress is provided by reduced glutathione, a major factor responsible for maintaining a reduced cellular environment. Reduced glutathione is reduced by NADPH through glutathione reductase, and reduced glutathione–dependent reactions with electrophilic and oxidizing species are catalyzed by glutaredoxins (9). A second key factor responsible for maintaining a reduced cellular environment is thioredoxin-1, a small (12 kDa) ubiquitously expressed protein that is reduced by electrons from NADPH through glutathione reductase and thioredoxin reductase (10). Peroxiredoxins (thioredoxin peroxidases) reduce hydrogen peroxide and alkyl hydroperoxides to water and alcohol using reducing equivalents derived from thioredoxin (11).

Oxidative stress results in a shift of the thiol-disulfide equilibrium of cellular proteins (12), activating transcription factors that mediate the induction of a variety of antioxidant enzymes. Activator protein-1 (AP-1) is an immediate early response transcription factor activated in response to oxidative stress. AP-1 is composed of Fos and Jun homodimers and heterodimers (reviewed in ref. 13) and the binding of AP-1 to
the AP-1 consensus sequence in the promoter of genes induces antioxidant enzymes, including glutathione S-transferase (GST; ref. 14), diphtheria toxin-diaphorase, and manganese superoxide dismutase (15). The antioxidant response element (ARE), a cis-acting regulator element in promoter region of antioxidant genes, such as GSTs, thioredoxin reductase-1, thioredoxin-1, and ferritin, as well as phase II xenobiotic metabolizing enzymes, is also activated by oxidative stress (reviewed in ref. 16). The transcription factors that bind to the ARE include the NF-E2–related factors 1, 2, and 3 (Nrf1, Nrf2, and Nrf3) that have been shown to positively (Nrf1 and Nrf2; refs. 17, 18) or negatively (Nrf3; ref. 19) regulate ARE-mediated gene expression. Nrf2 is normally sequestered in the cytoplasm by the Keap1-Cul3 complex where it is degraded by the ubiquitin-proteasomal pathway (20). However, under oxidative conditions, Nrf2 binding to Keap1 is inhibited and Nrf2 translocates from the cytoplasm to the nucleus where it heterodimerizes with a variety of basic leucine zipper transcription factors, including Jun (c-Jun, Jun-B, and Jun-D) and Maf (Maf G, Maf K, and Maf F) proteins (18, 21–23). This results in transactivation of AREs and the coordinated induction of antioxidant and phase II detoxification gene expression (18).

In the present study, we used transcription profiling analysis to identify an increase in antioxidant gene expression in peripheral blood mononuclear cells (PBMC) collected from patients treated with imexon during a phase I study. Many of these genes are known to be regulated by AP-1 and the ARE. Mechanistic studies revealed that imexon treatment increases nuclear Nrf2 levels in RPMI8226 myeloma cells and MDA-mb-231 breast cancer cells grown in vitro and increases both AP-1 and the ARE and binding in RPMI8226 cells and in normal PBMCs treated with imexon ex vivo. These findings suggest that imexon increases oxidative stress, which leads to an adaptive response involving up-regulation of several antioxidant defense genes. Part of the mechanism of action of imexon as an antitumor agent may be through an increase in oxidative stress. These antioxidant gene products also represent potential biomarkers for monitoring imexon activity in clinical studies.

Materials and Methods

Collection of patient PBMCs. Peripheral blood was obtained from either normal volunteers or patients enrolled in a phase I trial of imexon in patients with metastatic cancer or disseminated malignancy. The study was approved by the local institutional review board and patient informed consent was obtained. Approximately 10 mL of blood were collected immediately before treatment and 3 h after the end of a 1-h infusion of imexon. Samples were collected from a total of seven patients receiving doses of imexon ranging from 80 to 99.6% pure lyophilized white powder and has water solubility of 570 mg/m2. The patient tumor types were one melanoma, one lung, one breast, one prostate, one bladder, one colon, one ovary, two renal, one ovarian, and two ovarian. PBMCs were isolated by Ficoll (Amersham Biosciences, Pittsburgh, PA) centrifugation and stored at -80°C until RNA was isolated as described below.

RNA isolation and preparation. Total RNA was isolated from PBMCs using the GeneElute Mammalian Total RNA Miniprep kit (Sigma-Aldrich, St. Louis, MO) and was DNase treated using the DNA-Free kit (Ambion, Austin, TX). Total RNA was then treated with the RNeasy Clean-up kit (Qiagen, Valencia, CA) to remove any trace buffers from the isolation or DNasing steps. Two micrograms of total RNA were used for amplification. One round of amplification was done using the MessageAmp II aRNA kit (Ambion) according to the manufacturer’s instructions.

Microarray hybridizations. Probes were synthesized by using 5 µg of first round aRNA labeled with Alexa Fluor 647 (experimental) or Alexa Fluor 555 (control; Invitrogen, Carlsbad, CA). Samples were combined for each probe and purified using the QiAquick PCR purification kit (Qiagen). cDNA arrays of 22,000 human genes and expressed sequence tags (EST; Invitrogen) in duplicate were hybridized in triplicate for each sample as described previously (24). After washing, slides were coated with DyeSaver2 (Genisphere, Inc., Hatfield, PA) according to the manufacturer’s instructions. Slides were scanned using a ScanArray Express 5000 (Perkin-Elmer Life Sciences, Boston, MA) and quantitation was done using the Digital Genome AnalyzerDG software package (MolecularWare, Inc., Cambridge, MA). The spot intensity values were normalized according to each grid of the array (n = 48) by multiplying by a correction factor of the average intensity values for the reference channel divided by the test sample. The mean ratio from each duplicate, run in triplicate, was calculated as treated/control corrected values and reported as the average relative expression levels.

Quantitative real-time PCR. Quantitative real-time PCR was done using a PE Biosystems GeneAmp 5700 Sequence Detection System (Perkin-Elmer Life Sciences). Amplification reactions were set up in a reaction volume of 25 µL using the Applied Biosystems Taqman Universal PCR Master Mix (Appiera Corp., Applied Biosystems, Foster City, CA). PCR primers and Taqman probes were synthesized and preoptimized by Applied Biosystems (Assays-on-Demand). Each reaction containing PCR Master Mix, 900 nmol of each primer, and 250 nmol of the Fam probe was assayed in triplicate using 50 ng aRNA. Reverse transcription was done at 48°C for 30 min, and samples were incubated for 10 min at 95°C and then amplified over 40 cycles at 15 sec at 95°C followed by 1 min at 60°C. Quantitation was done using the comparative Ct method with β2-macroglobulin as the normalization gene.

Identification of ARE consensus sequences. Microarray gene ESTs were referenced to the Genebank accession nos., which were compared with the Genebank data base using BLAST to retrieve human gene sequences, which had an expected value (E) of 1e-09 or less and noncoding regions extrapolated and pattern matched using a PERL script for the consensus ARE (TGAG/CNNNGC) binding site consensus sequences (reviewed in ref. 25). All sequences were searched up to 10,000 bp unless another gene was found to be in that area. Complement sequences were also searched and reported when identified.

Cell culture conditions. The RPMI8226 myeloma cell line and MDA-mb-231 cell lines were obtained from American Type Culture Collection (Manassas, VA). RPMI8226 cells were maintained in RPMI 1640 supplemented with 5% heat-inactivated fetal bovine serum (Omega, Calabasa CA), 1 mmol/L L-glutamine, and 100 units/mL penicillin/streptomycin (Invitrogen), and MDA-mb-231 cells were maintained in DMEM supplemented with 10% fetal bovine serum (Omega). Imexon (4-imino-1,3-diazabicyclo[3.1.0]hexan-one; NSC-714597) was obtained from the Pharmaceutical Resources Branch of the National Cancer Institute (Bethesda, MD) under the Rapid Access to Intervention in Development Program. The drug was supplied as a 10,000 mg/mL lyophilized white powder and has water solubility of ~ 10 mg/mL. A stock solution (18 mmol/L) was prepared in water, sterile filtered, and stored at -80°C.

Electrophoretic mobility shift assays. Nuclear and cytoplasmic extracts were prepared from RPMI8226 myeloma cells as described previously (26). Double-stranded oligonucleotides (Santa Cruz Biotechnology, Santa Cruz, CA) corresponding to Nrf2 (5’5’CTCAGAT- TTTCGTTGATGACTCAGCCGGATCGCTCTGCTTAGTCATTGTCTTCC3) or the AP-1 consensus binding sequence (5’CGCGTTTGACCTGGCAGGT23) were radiolabeled using polynucleotide kinase (Roche, Indianapolis, IN), and unincorporated nucleotide was removed on a G50 spin column. Nuclear
Table 1. Antioxidant gene expression in PBMCs elevated following treatment with imexon

<table>
<thead>
<tr>
<th>Gene class</th>
<th>Ratios (Pt1, Pt2)</th>
<th>Putative ARE sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glutathione-based metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glutaredoxin-2*</td>
<td>(1.72, ND)</td>
<td>AGTGAGCCTGAGATCAGGCGACTCTTG</td>
</tr>
<tr>
<td>Glutathione peroxidase-1 (45)</td>
<td>(2.50, 0.32)</td>
<td>TGGAGCCCTGAGAGGCAAGGAGAG</td>
</tr>
<tr>
<td>Glutathione peroxidase-3*</td>
<td>(1.41, 3.56)</td>
<td>GCGACCCCTGAGTGGCCCCCACCC</td>
</tr>
<tr>
<td>Glutathione synthetase</td>
<td>(1.05, 1.79)</td>
<td>None identified</td>
</tr>
<tr>
<td>GSTA2 (45)</td>
<td>(0.52, 3.18)</td>
<td>TTGCGGTGAGACTGACATTGAT</td>
</tr>
<tr>
<td>GSTA3*</td>
<td>(2.81, 0.38)</td>
<td>GTAGAGTGTGACACCGCTGGTGC</td>
</tr>
<tr>
<td>GSTA4 (41)</td>
<td>(1.33, 2.92)</td>
<td>GGACCGCTGAGCTGGCCCTTGT</td>
</tr>
<tr>
<td>GSTM1 (41)</td>
<td>(3.17, ND)</td>
<td>GGCCGGCTGACTCTCGCTCCGGGA</td>
</tr>
<tr>
<td>GSTM4*</td>
<td>(3.03, ND)</td>
<td>GCTGTTGGAGCATAGAGCTCCATT</td>
</tr>
<tr>
<td>GSTMS (45)</td>
<td>(1.63, 1.77)</td>
<td>GGCGCCCTGACCTGCTGCTCCGGGA</td>
</tr>
<tr>
<td>GSTt-1*</td>
<td>(0.79, 2.41)</td>
<td>GGCGCCCTGACTGACACTGGGG</td>
</tr>
<tr>
<td>GSTt-1*</td>
<td>(1.96, 20.00)</td>
<td>GCCTGAGTACAGAGCAAGACATC</td>
</tr>
<tr>
<td>Microsomal GST1 (31)</td>
<td>(1.72, 1.43)</td>
<td>GATGCTTTGACGACGCCCCCTAAA</td>
</tr>
<tr>
<td>Iron handling</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ferritin light polypeptide (31)</td>
<td>(2.26, 7.43)</td>
<td>CTGAGATGTGACATAGCAGTGGTCT</td>
</tr>
<tr>
<td>Heme oxygenase (decycling) I (46)</td>
<td>(1.51, 0.15)</td>
<td>GAGGGTGGTGGAGGCAAGCAGTG</td>
</tr>
<tr>
<td>Transferrin*</td>
<td>(ND, 7.97)</td>
<td>TCCACCTGTGACTGCTCACTATG</td>
</tr>
<tr>
<td>Transferrin receptor (31)</td>
<td>(3.04, 3.13)</td>
<td>GACAAAGTGATGCCGGCTCAA</td>
</tr>
<tr>
<td>Oxygen-free radical metabolism</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NAD(P)H dehydrogenase, guinone 1 (31)</td>
<td>(0.71, 6.91)</td>
<td>GCGTGCTGAGACCCGACATT</td>
</tr>
<tr>
<td>Peroxiredoxin-1 (41)</td>
<td>(0.64, 3.22)</td>
<td>None identified</td>
</tr>
<tr>
<td>Peroxiredoxin-2 (31)</td>
<td>(1.34, 3.86)</td>
<td>GCCCGGGCTGAGAGCAGGCCGCCCGC</td>
</tr>
<tr>
<td>Peroxiredoxin-3*</td>
<td>(1.10, 2.13)</td>
<td>GGGGTGTTGAGCGGCGCCCTCTGSC</td>
</tr>
<tr>
<td>Peroxiredoxin-6*</td>
<td>(0.80, 2.16)</td>
<td>GCACAGTGGCTACGAGGCCCGCAT</td>
</tr>
<tr>
<td>Superoxide dismutase-1</td>
<td>(0.67, 1.71)</td>
<td>GCTGGTTGAGACAGAGCAGACCCC</td>
</tr>
<tr>
<td>Thioredoxin reductase-1 (47)</td>
<td>(2.90, ND)</td>
<td>AGAAAGCTCTGCTGGTCAAACT</td>
</tr>
<tr>
<td>Thioredoxin reductase-2*</td>
<td>(ND, 2.20)</td>
<td>GGGAGTTGAGCTCCTGAGGCTCC</td>
</tr>
<tr>
<td>NADPH generation (pentose phosphate pathway)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NADH dehydrogenase (ubiquinone)*</td>
<td>(2.18, 1.53)</td>
<td>None identified</td>
</tr>
<tr>
<td>Transketolase (31, 45)</td>
<td>(3.52,1,30)</td>
<td>GCTATTGGTACGACGACAGCATCT</td>
</tr>
</tbody>
</table>

Note: cDNA microarray was used to measure message expression pre-imexon infusion and 3 h post-imexon infusion in two patients. Patient 1 received 140 mg/m² and patient 2 received 430 mg/m² imexon. Ratios are of post-imexon/pretreatment values. Genes that have been reported previously to be Nrf2/ARE are referenced. Putative ARE consensus sequences are in italics. Abbreviation: ND, not detected.

*Indicates genes not reported previously to be regulated by Nrf2/ARE.

The results were adjusted for multiple comparisons using the Bonferroni correction. Thus, a statistically significant difference was 0.05/5 or 0.01.

Results

Antioxidant gene expression is increased in PBMCs after imexon treatment. PBMCs were obtained from seven patients treated with imexon enrolled in a phase I trial of imexon before and 3 h following a 1-h infusion. Samples from two patients, one with ovarian adenocarcinoma who received 140 mg/m² and patient 2 who received 430 mg/m² imexon, were used for cDNA microarray analysis. Patient 1 had a total of 5,856 genes/ESTs down-regulated and 2,840 genes/ESTs up-regulated (ratio > 2). A one-sample, two-sided t test was used to evaluate gene expression for the five-gene subset analyzed by quantitative real-time PCR testing the hypothesis that the fold elevation in expression of a particular gene was significantly different from 1.0.

extracts, 5 μg per reaction, were incubated with binding buffer [200 mmol/L Tris (pH 8.0), 1 mol/L NaCl, 40 mmol/L EDTA, 1.8 μg salmon sperm, 2% NP40, 40% bovine serum albumin] for 10 min at 4°C before addition of probe and then incubated for 20 min at room temperature. Reaction mixtures were separated on 6% acrylamide/Tris-borate EDTA gels, dried, and analyzed by PhosphorImager analysis using an MD Storm and ImageQuant software (Molecular Dynamics, Sunnyvale, CA). For competition assays, nuclear lysates were incubated with specific rabbit polyclonal antisera [1:40 dilution] for c-Jun or Jun-D (Santa Cruz Biotechnology) for 1 h at room temperature before the addition of the radiolabeled probe.

Western blotting. Western blots were done as described previously (7). A 1:1,000 dilution of rabbit polyclonal Nrf1 antibody, a 1:500 dilution of Nrf2 antibody, a 1:1,000 dilution of lamin A/C antibody, and a 1:2,000 dilution of actin antibody (all were from Santa Cruz Biotechnology) were used as primary antibodies. Antimouse, or antirabbit Ig, or antigen horseradish peroxidase–linked antibodies (Amersham Biosciences, Piscataway, NJ) were used as secondary antibodies. Detection was by chemiluminescence (NEL Life Science Products, Boston, MA) on Kodak Blm (Rochester, NY).

Statistical considerations. A one-sample, two-sided t test was used to evaluate gene expression for the five-gene subset analyzed by quantitative real-time PCR testing the hypothesis that the fold elevation in expression of a particular gene was significantly different from 1.0.
genes (Table 1). In addition, 8 of the other 10 up-regulated antioxidant genes were found to have a putative ARE consensus sequence in their promoter sequence, suggesting possible Nrf2/ARE regulation.

Five additional patient PBMC samples were examined by quantitative real-time PCR for expression of a subset of the antioxidant genes identified as up-regulated by microarray analysis. Three genes, thioredoxin reductase-2, glutaredoxin-2, and peroxiredoxin-3, were chosen because of their involvement in mitochondrial redox regulation (27–29). Thioredoxin reductase-1 and transferrin receptor were selected based on their previously identified ARE regulatory sequence and because both are Nrf2 regulated (30, 31). Thioredoxin reductase-1 expression was increased in all five patient samples following imexon treatment ($P = 0.004$; Table 2). However, variable responses were seen in the other gene products examined.

**Imexon treatment increases AP-1 DNA binding that is primarily mediated by c-Jun.** To investigate the molecular pathways responsible for imexon-induced antioxidant gene expression, electrophoretic mobility shift assay (EMSA) analysis was done using nuclear lysates prepared from RPMI8226 myeloma cells treated with 0, 100, 300, or 500 μmol/L imexon for 1, 4, and 16 h in vitro (Fig. 1A). These concentrations reflect a range that is achievable clinically at the MTD of 875 mg/m$^2$, which results in an average $C_{\text{max}}$ of 479 μmol/L and $C_{\text{ss}}$ of 34 μmol/L (32). Increased binding was observed to a probe corresponding to the AP-1 consensus sequence as early as 1 h following imexon treatment and remained elevated for up to 16 h. Similar results were obtained when PBMCs obtained from a normal volunteer were treated ex vivo with imexon in the same way (Fig. 2). To identify AP-1 binding proteins responsive to imexon treatment, EMSAs were done in the presence of antibodies to c-Jun and Jun-D (Fig. 1B). The addition of anti-c-Jun antibody resulted in nearly complete clearing of the AP-1 band. A lesser degree of clearing was observed with anti-Jun-D antibody, suggesting that the majority of the AP-1 DNA binding activity is due to c-Jun.

**Imexon treatment results in increased ARE DNA binding.** Because the ARE was identified in the promoter region of several genes whose expression was increased in response to imexon treatment, EMSA analysis was done using nuclear lysates prepared from PBMCs isolated from a healthy volunteer (Fig. 2) or RPMI8226 myeloma cells (Fig. 3) treated with 0, 100, 300, and 500 μmol/L imexon for 1, 4, and 16 h in vitro. Increased binding of ARE was seen after 4 h of imexon treatment but was decreased at higher concentration of imexon and with longer incubation times, suggesting an autoinhibition effect under these ex vivo conditions.

**Imexon treatment increases nuclear expression of Nrf2.** Because the Nrf2 transcription factor has also been shown to be redox-sensitive and to up-regulate antioxidant gene expression through the ARE, we investigated the ability of imexon treatment to translocate Nrf2 protein from the cytoplasm to the nucleus. As shown in Fig. 4A, an increase in Nrf2 in the nucleus was maximal after exposure of RPMI8226 cells to imexon for 4 h but decreased at 16 h and the highest imexon concentrations. Cytoplasmic Nrf2 levels were not changed by imexon treatment (Fig. 4B). Because Nrf1 has also been shown to bind to the ARE and to activate antioxidant gene expression, we

### Table 2. Increased PBMC antioxidant gene expression in patients receiving imexon ratio

<table>
<thead>
<tr>
<th>Gene</th>
<th>Patient dose, mg/m$^2$</th>
<th>80</th>
<th>105</th>
<th>325</th>
<th>430</th>
<th>570</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thioredoxin reductase 1</td>
<td>5.72</td>
<td>3.03</td>
<td>9.24</td>
<td>3.25</td>
<td>7.66</td>
<td></td>
</tr>
<tr>
<td>Thioredoxin reductase 2</td>
<td>2.00</td>
<td>0.61</td>
<td>0.25</td>
<td>0.95</td>
<td>3.28</td>
<td></td>
</tr>
<tr>
<td>Glutaredoxin-2</td>
<td>1.93</td>
<td>1.75</td>
<td>0.44</td>
<td>1.32</td>
<td>2.43</td>
<td></td>
</tr>
<tr>
<td>Peroxiredoxin-3</td>
<td>3.77</td>
<td>0.84</td>
<td>1.46</td>
<td>1.41</td>
<td>1.13</td>
<td></td>
</tr>
<tr>
<td>Transferrin receptor</td>
<td>23.34</td>
<td>0.33</td>
<td>20.00</td>
<td>1.80</td>
<td>3.51</td>
<td></td>
</tr>
</tbody>
</table>

NOTE: Quantitative real-time PCR was used to measure PBMC message expression in five patients before and 3 h after receiving an imexon infusion at doses shown. Values are the ratio of post-imexon/pretreatment measurements.
measured nuclear and cytoplasmic Nrf1 protein expression following imexon treatment (Fig. 4A and B). There were no significant changes in nuclear or cytoplasmic Nrf1 observed, except for a decrease in expression in both cytoplasmic and nuclear extracts at 16 h of 500 μmol/L imexon. Similarly, Nrf2 protein was increased in the nucleus of the MDA-mb-231 breast cancer cells (Fig. 4C). However, in this cell line, Nrf2 expression was maximal after 16 h compared with 4 h in the RPMI8226 cells.

Discussion

In the present study, we have shown that imexon treatment of patients in a phase 1 clinical trial resulted in activation of an apparent oxidative stress response in PBMCs involving up-regulation of antioxidant gene expression. Studies in RPMI8226 cells suggest that this response may involve both the c-Jun/AP-1 and the Nrf2 ARE response element pathways. It has been reported previously that, in vitro, imexon inhibits mitochondrial function leading to an increase in the formation of reactive oxygen species (5) and it depletes glutathione levels that could be responsible for the oxidative stress response seen (7).

AP-1 activation is an important early cellular response to oxidative stress, leading to the up-regulation of protective genes involved in cell proliferation, differentiation, apoptosis, angiogenesis, tumor invasion, as well as antioxidant defense genes (13, 33). AP-1 activity can be regulated by the type of dimer formation, posttranslational modifications, transcription, and interaction with other proteins, including Nrf2 (34, 35). Recombinant c-Jun DNA binding is increased by oxidant stress leading to AP-1 S-glutathiolation (36). AP-1 activation can also occur through oxidative activation of cytoplasmic mitogen-activated protein kinase family members, which phosphorylate c-Jun (reviewed in ref. 37). Based on the ability of imexon in increased oxidant stress (5, 7), activation of AP-1 by imexon could be due to redox modulation in the cytoplasm or nucleus.

Nrf2 is an activator of ARE-mediated gene expression and mediates the primary antioxidant response to an oxidative challenge in cells (17). Oxidizing stress releases Nrf2 from its cytoplasmic complexation with its cytoplasmic binding partner Keap-1, largely through modification of cysteine residues in Keap-1 (38). Some important ARE-regulated genes, which are controlled by Nrf2, include reduced glutathione synthesis enzymes (39), thioredoxin-1 (40), thioredoxin reductase-1 (40), glutathione peroxidase, glutathione reductase (41), and the glutathione transferases (42). We found many of these antioxidant genes to be up-regulated in PBMC of patients treated with imexon (Table 1). We also showed that imexon at the therapeutically achievable concentrations caused an increase in nuclear Nrf2 and binding of Nrf2 to the ARE in both PBMC and RPMI8226 cells. The effect decreased with longer exposure times and higher concentrations of imexon presumable due to the antioxidant defense mounted by the ARE.

Several anticancer drugs have been shown to increase reactive oxygen species, including doxorubicin, mitomycin C, arsenic trioxide, and motexafin-gadolinium, which may contribute to their antitumor activity (43, 44). Apparently, an increase in reactive oxygen species contributes to the antitumor activity of imexon, although this may not be the major mechanism. Thus, the effect of increased reactive oxygen species on antitumor activity may be self-limiting if there is an induced or constitutive increase in antioxidant enzymes. A consequence of an increase in reactive oxygen species is up-regulation of the expression of ARE-regulated antioxidant genes. Some of the genes we found to be up-regulated by imexon were also found to be increased in imexon-resistant RPMI8226 myeloma cells (8). Apparently, an increase in PBMC antioxidant gene expression, particularly of thioredoxin reductase, which showed the most consistent increased expression, could provide an early biomarker for response to imexon or adaptation to oxidative stress and other toxicities, although this possibility will require further studies.

In summary, we have found the up-regulation of many antioxidant genes in PBMCs collected from patients treated...
with imexon. Thioredoxin reductase-1 expression was the most consistently up-regulated antioxidant gene. Studies in RPMI8226 myeloma cells showed that imexon increased binding to the AP-1 and ARE consensus sequences, which regulate antioxidant gene expression. The results suggest that a prominent biological effect of imexon is a change in redox state that can be detected in surrogate normal tissue as increased antioxidant gene transcription.

References

25. Motohashi H, Yamamoto M. Nrf2-1 defines a...


The Antitumor Agent Imexon Activates Antioxidant Gene Expression: Evidence for an Oxidative Stress Response


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/13/11/3388

Cited articles
This article cites 47 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/13/11/3388.full#ref-list-1

Citing articles
This article has been cited by 2 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/13/11/3388.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.